EGFR and RAF1 fusions additionally displayed substantial cancer type-specificity, with 65% of 5′ EGFR fusions occurring in gliomas (Supplementary Fig. 6c) and 69% of 5′ RAF1 fusions occurring in thyroid carcinomas (THCAs) (Supplementary Fig. 6d). Here, RAF1 is linked to central nervous system cancer.